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The goal of this feasibility study was to examine whether sonoporation assisted transduction of siRNA
could be used to ameliorate arthritis locally. If successful, such approach could provide an alternative
treatment for the patients that have or gradually develop adverse response to chemical drugs. Tumor
necrosis factor alpha (TNF-a) produced by synovial ﬁbroblasts has an important role in the pathology
of rheumatoid arthritis, inducing inﬂammation and bone destruction. In this study, we injected a mixture
of microbubbles and siRNA targeting TNF-a (siTNF) into the articular joints of rats, and transduced siTNF
into synovial tissue by exposure to a collimated ultrasound beam, applied through a probe 6 mm in diam-
eter with an input frequency of 3.0 MHz, an output intensity of 2.0 W/cm2 (spatial average temporary
peak; SATP), a pulse duty ratio of 50%, and a duration of 1 min. Sonoporation increased skin temperature
from 26.8 C to 27.3 C, but there were no adverse effect such as burns. The mean level of TNF-a expres-
sion in siTNF-treated knee joints was 55% of those in controls. Delivery of siTNF into the knee joints every
3 days (i.e., 7, 10, 13, and 16 days after immunization) by in vivo sonoporation signiﬁcantly reduced paw
swelling on days 20–23 after immunization. Radiographic scores in the siTNF group were 56% of those in
the CIA group and 61% of those in the siNeg group. Histological examination showed that the number of
TNF-a positive cells was signiﬁcantly lower in areas of pannus invasion into the ankle joints of siTNF-
than of siNeg-treated rats. These results indicate that transduction of siTNF into articular synovium using
sonoporation may be an effective local therapy for arthritis.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The goal of this feasibility study was to examine whether
sonoporation assisted transduction of siRNA could be used to
ameliorate arthritis locally. If successful, such approach could
provide an alternative treatment for the patients that have or
gradually develop adverse response to chemical drugs. Synovial
macrophages in patients with rheumatoid arthritis (RA) produce
tumor necrosis factor alpha (TNF-a), a central component in the
cytokine cascade. TNF-a acts on synovial ﬁbroblasts [1], inducing
the expression of inﬂammatory mediators such as interleukin(IL)-1, IL-6, IL-18, IL-32, IL-15, IL-12, and IL33 [2], indicating the
important role of TNF-a in the pathophysiology of RA. In addition,
inﬂammatory cytokines including TNF-a are potent inducers of
bone destruction [3], and cause joint dysfunction [4]. Thus,
synovial tissue, which produces inﬂammatory cytokines, is an
important target tissue in RA treatment. Biological drugs target-
ing TNF-a or its receptors have been found to reduce synovitis
and/or bone destruction in RA, and they have been widely used
in clinical settings [5]. Although these biological drugs are more
effective than conventional anti-rheumatic drugs [6,7], they have
several problems, including patients who cannot receive beneﬁt
from these drugs [8], nonuniform effects in different joints [9]
and are higher cost than other drugs for RA [10]. Thus, low-cost
treatment methods that can control the local production of
TNF-a are required.
RNA interference (RNAi) is a technique in which gene expres-
sion is silenced by sequence speciﬁc small interfering RNAs
(siRNAs), 21–23 bases in length. The effectiveness of the RNAi
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and this method has since been used widely in applications such as
gene function analysis [11]. Since 2003, when an siRNA was shown
to be therapeutically effective in a hepatitis model [12], many
types of siRNAs have been tested in various disease models. Clini-
cal trials have shown the effectiveness of siRNAs for the treatment
of malignant tumors, including hepatic cancer [13], and ophthal-
mological diseases, such as neovascular age-related macular
degeneration [14] and diabetic macular edema [15], suggesting
that siRNAs may become a useful class of therapeutic drugs.
The in vivo siRNA introduction methods include virus vectors,
gene guns, hydrodynamic injection, electroporation, and sonopora-
tion. Virus vectors utilize viruses from which disease-related genes
have been replaced by target genes. Hydrodynamic injection in-
volves the relatively rapid injection of a large volume of solution
into the bloodstream, overcoming the physical barriers of the
endothelium and cell membranes. Gene guns use helium gas to
shoot microscopic gold beads covered with DNA into tissue con-
taining target cells in the superﬁcial layers [16]. We previously uti-
lized electroporation to transduce siRNAs targeting TNF-a and IL-6
into the articular synovium, ﬁnding that the inhibition of expres-
sion of these genes has therapeutic effects in an arthritis model
[17,18]. These results indicated that local gene silencing of inﬂam-
matory cytokines in the synovial membrane could control synovial
inﬂammation and bone destruction.
Due to safety concerns, we have utilized sonoporation to trans-
duce siRNA into cells in vivo. Sonoporation is a method for gene
transduction that makes use of ultrasounds. Ultrasound is already
widely utilized in daily clinical practice. As no adverse biological
effects have been associated with ultrasonic applications, we re-
garded sonoporation as a safe technique for gene transduction.
We therefore utilized sonoporation to transduce siRNA targeting
TNF-a (siTNF) into the synovium of a rat arthritis model and ana-
lyzed the safety and efﬁcacy of this method.
This paper is organized in the following way. In Section 2, Mate-
rials and methods, in Section 3, Results, and in Section 4,
Discussion.2. Materials and methods
2.1. In vitro siRNA transfection
Because siRNA can inhibit genes unrelated to the target gene
(off-target effect), two commercially available siRNA duplexes tar-
geting the rat TNF-a gene were synthesized, one (A) being 50-ACAU
CUCGGAUCAUGCUUUCCGUGC-30 and 50-GCACGGAAAGCAUGAUCC
GAGAUGU-30; and the other (B) being 50-AAGAGAACCUGGGAGUAG
AUAAGGU-30 and 50-ACCUUAUCUACUCCCAGGUUCUCUU-30 (Invit-
rogen, Carlsbad, CA). To determine the most effective siRNA se-
quences for suppression of TNF-a expression in rats, each siRNA
was transfected into cultured rat synovial ﬁbroblasts, obtained as
described [19]. Synovial ﬁbroblasts (2  105 cells/well) were
seeded onto 6-well plates (Iwaki Glass, Chiba, Japan). After 24 h,
the culture medium was aspirated, and 1.9 ml of fresh complete
medium was added. A mixture of siRNA (200 pmol), 7.5 ll of
RNAiFect Transfection Reagent (Qiagen, Hilden, Germany), and
90 ll of Buffer EC-R (Qiagen) was added to each well. All Stars
Negative Control siRNA (Qiagen) was used as a nonspeciﬁc siRNA
control (siNeg).2.2. Electroporation-assisted siRNA transduction in vivo
We previously succeeded in transducing various genes using
electroporation [17,18,20,21]. Thus, as a positive control to conﬁrm
the transduction of ﬂuorescently labeled siRNA, electroporationwas used. All animal experiments were performed in accordance
with the guidelines of Kyoto Prefectural University of Medicine.
Male Dark Agouti (DA) rats weighing 100–140 g were purchased
from Shimizu Laboratory Suppliers (Kyoto, Japan). Rats were anes-
thetized by intraperitoneal injection of 1 ll/g sodium pentobarbi-
tal, and 50 ll of siRNA/siPORT Amine (Ambion, Austin, TX)
complex containing 800 pmol siRNA and 10 ll siPORT Amine was
administered into the left knee joint of each rat using a 27-gauge
needle. Immediately afterward, the knee joint was coated with ker-
atin cream (Fukuda Denshi, Tokyo, Japan) onto which a pair of elec-
trode pads (1.0 cm in diameter) were placed. Using a CUY21
electric pulse generator (NepaGene, Tokyo, Japan), three square-
wave pulses, each 100 msec in length, were loaded at 150 V/cm
at a frequency of 1 s1 followed by two other pulses with the oppo-
site polarity.2.3. Sonoporation-assisted siRNA transduction in vivo
The rats were anesthetized by intraperitoneal administration of
sodium pentobarbital (Dainippon Pharmaceutical, Osaka, Japan),
and the hair around the left knee was shaved off. Aliquots of
10 ll of SV-25 microbubbles (NepaGene) were added to 40 ll
of siRNA, and the mixtures were injected into the left knee joint
of the rats using a syringe equipped with a 27-gauge needle. Imme-
diately after injection, ultrasound conduction gel (Rich-Mar, Inola,
OK) was painted onto the skin around the knee. Using a Sonitron
2000 V (Serial No. 0624081173, NepaGene), a collimated ultra-
sound beam was applied for 1 min through a probe 6 mm in diam-
eter with an input frequency of 3.0 MHz, an output intensity of
2.0 W/cm2 (spatial average temporary peak; SATP), and a pulse
duty ratio of 50%; these sonoporation conditions have been
described previously [22]. The probe was put onto the skin around
patella, and ultrasound beam was emitted to reach articular
synovium.2.4. Animals and induction of collagen-induced arthritis
Our method of gene inhibition using a rat collagen-induced
arthritis (CIA) model has been described [23]. Brieﬂy, DA rats,
weighing 100–140 g, were purchased from Shimizu Laboratory
Suppliers (Kyoto, Japan). Collagen type II (Collagen Research Cen-
ter, Tokyo, Japan) was dissolved in 0.01 M acetic acid (2 mg/ml)
and emulsiﬁed 1:1 in Freund’s incomplete adjuvant (Sigma, St.
Louis, MO) (CII/FIA) on ice. Each rat was intradermally injected
with 200 ll CII/FIA solution at the base of the tail [23].2.5. Ultrasound output measurement
Ultrasound output was measured using an ultrasound power
meter (Ohmic Instruments, Easton, MD) (Fig. 1A). The distance
from a transducer emitting ultrasound waves to the probe tip
was 45 mm. The ultrasound waves were examined using a cali-
brated hydrophone (u2.4 mm, ONDA, Sunnyvale, CA), which was
ﬁxed 5 mm from the probe in a degassed water tank, and analyzed
using Acoustic Intensity Measurement System (Ito Co. Ltd., Tokyo,
Japan) (Fig. 1B). A cross-sectional diagram of the ultrasound wave
was analyzed at 6.35 mm  6.35 mm, and the effective radiating
area (ERA) and beam non-uniformity ratio (BNR) were measured.
Two-dimensional images were constructed, and were also assessed
as three-dimensional images. In analyzing the ultrasound wave
cross-sections, the analytical capability of the hydrophone was ta-
ken into account, and analysis was performed at 0.3 W/cm2 with a
100% duty cycle. The same hydrophone was used to measure the
frequency.
Fig. 1. Ultrasound with measurement device. Ultrasound power meter (A) and Acoustic Intensity Measurement System (B) were used in measuring output ultrasound waves
(": Hydrophone and Sonitron 2000 V probe).
876 H. Inoue et al. / Ultrasonics 54 (2014) 874–8812.6. Measurement of temperature at the surface of the rat knee joint
A digital thermometer (Unique Medical, Tokyo, Japan) was used
to measure skin temperatures. Immediately after sonoporation, a
temperature probe (0.5 mm) was set onto the surface of each rat
knee joint. Temperatures were measured and recorded (n = 4).2.7. Real-time RT-PCR analysis
Total RNA was extracted from tissue samples using Sepasol-
RNA super II (Nacalai Tesque, Kyoto, Japan) and puriﬁed as de-
scribed by the manufacturer. These RNAs were reverse transcribed
using a PrimeScript™ RT reagent kit (Takara Bio, Otsu, Japan), as
described by the manufacturer. Quantitative real-time RT-PCR
was performed using a Biosystem 7300 cycler (Applied Biosystems,
Foster City, CA) by monitoring the increase in reporter ﬂuorescence
of Universal Probe Library (UPL) Probes (Roche Diagnostics, Basel,
Switzerland) for TNF-a. The PCR primers were designed by Custom
Primer Service (Invitrogen). Aliquots of 2 ll of cDNA (100 ng) were
ampliﬁed using 200 nM forward and reverse primers, 100 nM UPL
probe, and 12.5 ll of TaqMan Gene Expression PCR Master Mix
(Applied Biosystems) in a total volume of 25 ll. The ampliﬁcation
protocol consisted of 40 cycles of denaturation at 95 C for 15 s and
extension and annealing at 60 C for 1 min. The TNF-a speciﬁc pri-
mer were 50-CGTAGCCCACGTCGTAGC-30 (forward) and 50-GGTTGT
CTTTGAGATCCATGC-30 (reverse), with the probe consisting of
Roche UPL probe #78. The 18S ribosomal RNA speciﬁc primers
were 50-ATGAGTCCACTTTAAATCCTTTAACGA-30 (forward) and
50-CTTTAATATACGCTATTGGAGCTGGAA-30 (reverse), and the probe
was 50-[FAM] ATCCATTGGAGGGCAAGTCTGGTGC [BHQ]-30 (Table 1).
Changes in gene expression were quantiﬁed using the comparative
CT method, which was used to calculate the relative changes in
TNF-a expression normalized relative to changes in 18S ribosomal
RNA as an internal control.Table 1
Primers used for real-time RT-PCR.
Gene Primer sequence
TNF-a Forward: GTAGCCCACGTCGTAGC
Reverse: GTTGTCTTTGAGATCCATGC
18S ribosomal RNA Forward: ATGAGTCCACTTTAAATCCTTTAACGA
Reverse: CTTTAATATACGCTATTGGAGCTGGAA2.8. Evaluation of the silencing effects of siRNA in vivo
To analyze TNF-a mRNA expression in vivo, the synovium was
removed from the region surrounding the left patella of rats 24 h
after sonoporation-assisted siRNA transduction; the synovium
from rats administered nonspeciﬁc siRNA served as a control. Iso-
lation and reverse transcription of total RNA, as well quantitative
real-time PCR, were performed as described above. TNF-a gene
expression was normalized relative to 18S ribosomal RNA as an
internal control.2.9. Fluorescence microscopy
Fluorescently labeled Silencer FAM™-Labeled Negative Con-
trol #1 siRNA (Ambion, Austin, TX) was injected into rat synovium,
with siPORT Amine by electroporation or with microbubbles by
sonoporation. One day later, the injected knee joint was resected
and examined under a ﬂuorescence stereomicroscope (SZX12;
Olympus, Tokyo, Japan).2.10. Evaluation of CIA rats
CIA rats were immunized as described. The rats were anesthe-
tized by an intraperitoneal injection of 1 ml/g sodium pentobarbi-
tal and siRNA was sonoporated every 3 days (i.e., 7, 10, 13, and
16 days after immunization). Foot volume was measured using a
water replacement plethysmometer (Unicom Japan, Tokyo, Japan)
[24]. The cumulative percentage of rats with swollen ankles of
the lower limb on the treated side was calculated to determine
the chronology of onset of CIA. Twenty-eight days after immuniza-
tion, radiographs were taken of the hind paws of CIA rats using a
Technomobile II (Hitachi, Tokyo, Japan) at 50 kV/2.0 mAs, at a fo-
cus-skin distance of 100 cm. Bone and cartilage destruction were
classiﬁed and scored as: 0 = no bone damage; 1 = tissue swelling
and edema; 2 = joint erosion; and 3 = bone erosion and osteophyte
formation. The left knee and ankle joints of each rat were excised
and ﬁxed in 3.7% formaldehyde. Following decalciﬁcation with for-
mic acid, sagittal sections 6 mm in thickness were prepared from
the center of the lateral condyle of the femur, as well as from the
center of the foot joint. To investigate the effects of siTNF on the
ankle synovium, sections were stained with anti-TNF-a antibody
(ab1793; abcam, Cambridge, MA).
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Fig. 2. Inhibition of TNF-a mRNA expression in vitro. Two siRNA duplexes speciﬁc
for rat TNF-a (siTNF-a and siTNF-B, n = 3 each) were transfected into synovial
ﬁbroblasts derived from DA rats, while nonspeciﬁc siRNA (siNeg, n = 3) was
transfected as a control. The relative expression of TNF-a was examined by real-
time PCR. P < 0.05 vs. nonspeciﬁc siRNA.3. Results
3.1. Gene silencing effects of TNF-speciﬁc siRNA (siTNF) in vitro
Two siRNA duplexes targeting rat TNF-a were transfected into
cultured FLS to compare their ability to inhibit TNF-a expression.
Transfection of the siTNF-A and siTNF-B duplexes reduced TNF-a
expression to 45% and 26%, respectively, of their levels in siNeg
treated cells. These results conﬁrmed that gene silencing was not
due to an off-target effect, and TNF-a-speciﬁc siRNA-B was used
for subsequent experiments (Fig. 2).3.2. Ultrasound output
Theaverageultrasoundwaveoutputwas0.282W,anddividing the
output by the area of the probe tip (0.3 cm2 p) gave 1.00W/cm2.
This result did not contradict a 2.00 W/cm2, 50% duty cycle, which
is the output setting for the sonoporator. ERA was 0.365 cm2, and
BNRwas 3.762. The two-dimensional image of the ultrasoundwave
and its constructed three-dimensional image are shown in the
ﬁgures (Fig. 3A and B). The frequency was 3.101 MHz, which was
almost the same as that of the output setting of the sonoporator
(Fig. 3C).Fig. 3. Output parameter of sonicator. A three-dimensional image was created (B) by
Intensity Measurement System. On a screen showing the ultrasound waveform, it is show
the output setting for the sonoporator.3.3. Skin temperatures after sonoporation
Knees were exposed to sonoporation for 1 min in order to deter-
mine its effect on skin temperature. Mean skin temperatures be-
fore and soon after sonoporation were 26.8 ± 0.19 C and
27.3 ± 0.03 C, respectively (Fig. 4).3.4. Gene silencing effects of siTNF in vivo
To determine the in vivo silencing effect of siTNF transduced by
sonoporation, we utilized real-time RT-PCR to measure TNF-a
mRNA expression in rat synovium. The mean levels of TNF-aconstructing aggregated two-dimensional images (A) obtained using the Acoustic
n that (a) is 2.5 ls. The frequency was 3.101 MHz (C), which is almost the same as
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Fig. 4. Skin temperature of rat knee joints. Skin temperatures in 4 knee joints were
measured before and soon after sonoporation.
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Fig. 5. Inhibition of TNF-amRNA expression in vivo. Synovial tissues were obtained
from the knee joints of DA rats 24 h after sonoporation-assisted siRNA transduction.
The relative expression of TNF-a was examined by real-time PCR. P < 0.05 vs. non-
speciﬁc siRNA, #P < 0.05 vs. control.
878 H. Inoue et al. / Ultrasonics 54 (2014) 874–881expression in the knee joints were 55% of those in synovium of the
control group (Fig. 5).3.5. Transduction of ﬂuorescently labeled siRNA into rat knee
synovium
We utilized ﬂuorescently labeled siRNA to determine whether it
was transfected by sonoporation into synovial tissue. Fluorescence
microscopy showed that electroporation transduced labeled siRNA
into the synovium (Fig. 6C and D). Using microbubbles and
ultrasonication at 2.0 W/cm2, green ﬂuorescence was observed in
synovial tissue one day later. Green ﬂuorescence was also seen in
the synovium around the patella, femur, and tibia, with no ﬂuores-
cence seen in the surface layer of the articular cartilage (Fig. 6E and
F). No green ﬂuorescence was detected in the synovium of the
knees transduced with ﬂuorescently labeled nonspeciﬁc siRNA by
sonoporation (Fig. 6G and H).Fig. 6. Sonoporation-mediated transduction of ﬂuorescently labeled siRNA into synovium
with siPORT Amine by electroporation (C, D) or with microbubbles by sonoporation (E,3.6. Therapeutic effects of sonoporated TNF-a-speciﬁc siRNA in CIA
rats
We examined whether the sonoporation of siTNF into rat knee
joints reduced the clinical manifestations of arthritis. In vivo sono-
poration of speciﬁc siRNA into the knee joint every 3 days (i.e., 7,
10, 13, and 16 days after immunization) resulted in signiﬁcant
inhibition of paw swelling 20–23 days after immunization, as well
as a marked delay in the onset time of symptoms compared with
controls (Fig. 7B). These effects were not observed in rats treated
with nonspeciﬁc siRNA. Although a low level of paw swelling
was observed in siTNF treated rats beyond 24 days, it was not sig-
niﬁcant compared with the other two groups, and the cumulative
incidence of paw swelling did not reach 100% (Fig. 7A). Macro-
scopic views of the lower limbs on day 28 showed that the degree
of paw swelling in the siTNF group was milder than in the other
groups (Fig. 7C). Radiographic evaluation of the paws 28 days after
immunization showed that the joint space could not be clearly
visualized, while the talus was severely destroyed; in contrast,
treatment with siTNF almost completely abrogated talus destruc-
tion (Fig. 7D). The radiographic scores in siTNF group were signif-
icantly reduced, to 56% compared with the CIA group and to 61%. Scheme of a joint (A, B). Fluorescently labeled siRNA was administered to the joints
F). siNeg was injected with microbubbles by sonoporation (G, H).
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Fig. 7. Therapeutic effect of sonoporated siTNF and radiological evaluation in CIA rats. Rats were immunized with type II collagen (day 0), and intraarticularly sonoporated
with siTNF (circles, n = 22) or siNeg (triangles, n = 23) on days 7, 10, 13, and 16 (arrows). CIA rats were immunized with type II collagen but not siRNA (crosses, n = 21). The
cumulative incidence of paw swelling (A) and kinetic changes in paw volume (means ± SD) (B) were plotted. P < 0.05 vs. siNeg, #P < 0.05 vs. CIA. (C) Representative
macroscopic views of the lower limbs on day 28. On day 28, radiographic imaging of paws was performed. (D) Representative radiographic images and (E) radiographic scores
(means ± SE) on day 28. (F) Histological demonstration of TNF-a speciﬁc staining on day 28. P < 0.05 vs. siNeg, #P < 0.05 vs. CIA.
H. Inoue et al. / Ultrasonics 54 (2014) 874–881 879compared with the siNeg group. These ﬁndings indicated that
destruction of the joints was signiﬁcantly milder in rats treatedwith siTNF than in those treated with siNeg (Fig. 7E). Moreover,
siTNF had no adverse effects, such as burns or tissue destruction.
Table 2
Ultrasonic condition of gene transduction.
Tissue Frequency (MHz) Intensity (W/cm2) Duration of time (s) Pulse duty ratio (%) Mechanical index
Myocardium [32] 1 1.0–2.0 60 10–50 –
Kidneys [33] 1 – 60 Continuous –
Peritoneal cavity [34] 1 2.0 105 20 –
Pancreas [35] 1.3 – 1200 Continuous 1.2–1.4
Lungs [36] 1 3.0 – 20 –
Corneas [37] 1 1.0–2.0 120 50 –
Intervertebral discs [38] - 0.3–2.0 10–120 – –
Tumors [39] 7 – 540 – 1.9
Synovium (this study) 3 2.0 60 50 –
880 H. Inoue et al. / Ultrasonics 54 (2014) 874–881Histological examination of the paws showed that the number of
TNF-a positive cells was signiﬁcantly lower in areas of pannus
invasion into the ankle joints of the siTNF- than of the siNeg-trea-
ted rats (Fig. 7F).4. Discussion
Ultrasound is widely used in clinical practice, with output set-
tings, including waveform (continuous or pulsed wave), frequency,
intensity, and duration of time, varying according to the purpose of
the examination [25]. Application of ultrasound to living tissue is
expected to induce heating or vibration. Continuous waves are ex-
pected to show mainly thermal effects, while pulsed waves are ex-
pected to show primarily non-thermal effects. Continuous wave
ultrasound is used to treat patients with chronic low back pain,
with an intensity of 1.5 W/cm2, a frequency of 1 MHz, and duration
of 1 min, continuous wave signiﬁcantly improving regarding func-
tion and global pain compared with a placebo control group
(p < 0.001) [26]. We found that sonoporation did not markedly ele-
vate skin temperature and BNR was enough low, suggesting that
this method was safe for siRNA transduction.
Pulsed wave ultrasound enhanced cell membrane permeability,
making it suitable for gene transduction. Enhancing membrane
permeability allows substances that do not usually enter cells to
be delivered, a technique called sonoporation [27,28]. However,
ultrasound contrast agents are usually used because of the inefﬁ-
ciency of transduction by sonoporation alone [29,30]. Sonopora-
tion with microbubbles has been shown to be capable of
delivering genes to tissues, such as the myocardium [31], kidneys
[32], peritoneal cavity [33], pancreas [34], lungs [35], corneas
[36], intervertebral discs [37], and tumors [38] (Table 2). Thus,
ultrasound is used for gene transduction with various conditions,
considered to be a potent method toward clinical use. In 2007,
we reported that plasmid DNA encoding luciferase was transduced
into normal synovial tissue by sonoporation, with the efﬁciency of
transduction being signiﬁcantly higher with a combination of
microbubbles and sonoporation than with sonoporation alone
[22]. In the present study, we used the combination of sonopora-
tion and microbubbles to successfully deliver siTNF into the syno-
vium of an arthritis model. Nevertheless, the intensity of
ultrasound is important for gene transduction because cell mem-
brane permeability is dependent on cavitation resulting from ultra-
sonication [39]. We therefore sonoporated articular synovia at
output intensities of 0.5, 1.0, and 2.0 W/cm2, ﬁnding that the efﬁ-
ciency of transduction was highest at 2.0 W/cm2 [22]. No adverse
effects, such as burns or tissue destruction, were observed, indicat-
ing that this gene transduction method is safe.
Factors involved in the pathophysiology of RA include cells such
as T cells, macrophages, and synovial ﬁbroblasts, and cytokines
such as TNF-a, IL-1, IL-6, IL-18, IL-32, IL-15, IL-12, and IL-33 [2].
TNF-a produced by activated macrophages plays an important role
[40] in inducing the production of other inﬂammatory cytokines[1]. Hence, several biological drugs targeting TNF-a are used clini-
cally, including inﬂiximab [5], etanercept [6], adalimumab [41],
and golimumab [7]. Combining these biological drugs with metho-
trexate, the basic drug for RA, can improve the therapeutic effects
of the latter, even in patients in whom methotrexate monotherapy
is ineffective. Although biological drugs are administered systemi-
cally, their effects on various joints may not be uniform. Moreover,
systemic administration is not suitable for patients with monoar-
thritis, due to adverse effects. Rather, these patients require local
inhibition of arthritis. However, the efﬁcacy of local treatment with
biological drugs is unclear [42–45]. An insufﬁcient treatment effect
may be due to insufﬁcient neutralization of TNF-a in synovial ﬂuid
or the inability of these drugs to reach the cells that produce cyto-
kines [45]. To overcome these problems, we have evaluated a local
method of gene inhibition that acts directly on cells. Using speciﬁc
siRNA, we knocked down TNF-a gene expression speciﬁcally in the
synovium. Production of TNF-a protein in the ankle joint synovium
of siTNF treated CIA rats was lower than that in CIA group or siNeg
treated CIA rats. The siTNF acts speciﬁcally on TNF-a and may also
inhibit inﬂammatory factors downstream of this cytokine, as well
as controlling synovitis. Moreover, since TNF-a induces bone
destruction by acting on osteoclasts directly [46] or indirectly
[3], and TNF-a inhibitors used clinically have inhibitory effects
against bone destruction [47], siTNF may also inhibit bone destruc-
tion. Indeed, we found that radiological scores in the siTNF trans-
duction group were signiﬁcantly lower than in the other groups.
These ﬁndings suggest that siTNF may have inhibited bone
destruction by suppressing osteoclast differentiation.
In conclusion, transduction of siTNF into CIA rats by sonopora-
tion inhibited arthritis. Our ﬁndings indicate that sonoporation is a
safe method for gene transduction, with no adverse effects. Local
gene transduction by sonoporation may help in the treatment of
arthritis that cannot be controlled sufﬁciently by systemic admin-
istration of biologic drugs.
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